Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE STUDY IS DESIGNED TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF NXP900 IN COMBINATION WITH OSIMERTINIB IN PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATED (EGFR MUT+) NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE CANCERS INITIALLY RESPONDED TO TREATMENT WITH OSIMERTINIB BUT SUBSEQUENTLY ACQUIRED RESISTANCE TO TREATMENT THE STUDY IS DESIGNED TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF NXP900 IN COMBINATION WITH OSIMERTINIB IN PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATED (EGFR MUT+) NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE CANCERS INITIALLY RESPONDED TO TREATMENT WITH OSIMERTINIB BUT SUBSEQUENTLY ACQUIRED RESISTANCE TO TREATMENT

NUVECTIS PHARMA ANNOUNCES THE INITIATION OF THE PHASE 1B STUDY OF NXP900 IN COMBINATION WITH OSIMERTINIB IN PATIENTS WITH NSCLC

FORT LEE, NJ, NOV. 25, 2025 (GLOBE NEWSWIRE) -- NUVECTIS PHARMA, INC. (NASDAQ: NVCT, THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF INNOVATIVE PRECISION MEDICINES FOR THE TREATMENT OF SERIOUS CONDITIONS OF UNMET MEDICAL NEED IN ONCOLOGY, TODAY ANNOUNCED THAT THE COMPANY WILL HOST A VIRTUAL KEY OPINION LEADER MEETING ON TUESDAY, DECEMBER 2, 2025 AT 8:00 AM ET TO DISCUSS THE NXP900 PHASE 1B PROGRAM IN ADVANCED SOLID TUMORS, INCLUDING THE COMBINATION WITH OSIMERTINIB IN NON-SMALL CELL LUNG CANCER. TO REGISTER FOR THE EVENT, CLICK HERE.

NUVECTIS PHARMA TO HOST A VIRTUAL KEY OPINION LEADER MEETING TO DISCUSS THE NXP900 PHASE 1B PROGRAM IN ADVANCED SOLID TUMORS, INCLUDING THE COMBINATION WITH OSIMERTINIB IN NSCLC

FORT LEE, N.J., NOV. 04, 2025 (GLOBE NEWSWIRE) -- IN A RELEASE ISSUED UNDER THE SAME HEADLINE ON NOVEMBER 4, 2025 AT 07:30 ET BY NUVECTIS PHARMA, INC. (NASDAQ: NVCT), THE TABLES WERE NOT INCLUDED. THE TABLES HAVE BEEN ADDED AND THE CORRECTED RELEASE FOLLOWS:

Nuvectis Pharma, Inc.

NVCT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Nuvectis Pharma, Inc.

NVCT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NVCT